Company Filing History:
5 out of 15,471 
1 out of 376 
2 out of 832,812 Years Active: 2003-2020
Title: Richard Syd Kornbluth: Innovator in Immunology and Cancer Treatment
Introduction: Richard Syd Kornbluth, based in La Jolla, CA, is a prominent inventor recognized for his significant contributions to immunology and cancer therapies. With a portfolio of 8 patents, Kornbluth’s work is at the frontier of using fusion proteins to bolster immune responses against infectious diseases and cancer cells.
Latest Patents: Kornbluth’s most recent patents focus on advanced compositions tailored for immunotherapy. One notable invention comprises antigens linked to a TNF superfamily ligand, resulting in fusion proteins that serve as vaccine adjuvants. These proteins enhance immune responses against various pathogens and tumors. Specifically, this invention includes a unique fusion polypeptide that self-assembles into multiple-trimer forms of CD40 ligand, which can be delivered as isolated proteins or via DNA vaccination methods, including viral vectors like adenoviruses.
Another significant patent addresses methodologies for developing self-adjuvanting vaccines. This invention combines an immunostimulatory intracellular signaling peptide with a multimerization peptide, aimed at enhancing immune responses to prevent or treat infections and hyperproliferative diseases such as cancer. The applications of this technology hold promise for therapeutic effects in humans as well as non-human mammals, birds, and fish.
Career Highlights: Throughout his career, Richard has been affiliated with esteemed research institutions, notably the University of California. His work at this institution has been pivotal in advancing innovative treatments that aim to combat infectious diseases and malignancies by tapping into the body’s immune response mechanisms.
Collaborations: Kornbluth has collaborated with several notable individuals in the field, including Geoffrey William Stone and Eyal Raz. These partnerships have allowed him to broaden the scope of his research and to integrate diverse perspectives into his innovative approaches to immunotherapy.
Conclusion: Richard Syd Kornbluth stands out as a vital contributor to modern medicine, particularly in the realms of immunology and cancer treatment. His patents not only exemplify his innovative spirit but also reflect his commitment to enhancing therapeutic strategies through scientific ingenuity. As research continues to evolve, Kornbluth's work is likely to play a significant role in shaping future medical advancements.